What is HC Wainwright’s Estimate for COYA Q1 Earnings?

Coya Therapeutics, Inc. (NASDAQ:COYA) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Coya Therapeutics in a note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.66) EPS.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The business had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Stock Performance

Shares of COYA opened at $4.22 on Tuesday. Coya Therapeutics has a fifty-two week low of $3.94 and a fifty-two week high of $7.75. The firm has a market cap of $99.00 million, a price-to-earnings ratio of -3.32 and a beta of 0.23. The firm has a 50 day moving average price of $4.68 and a 200-day moving average price of $5.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $192,000. Occudo Quantitative Strategies LP purchased a new position in Coya Therapeutics during the fourth quarter valued at $66,000. Millennium Management LLC purchased a new position in Coya Therapeutics during the fourth quarter valued at $121,000. 683 Capital Management LLC bought a new stake in shares of Coya Therapeutics during the 4th quarter valued at $465,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Coya Therapeutics in the 4th quarter worth about $128,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics News Roundup

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and an $18 price target on COYA, representing a large upside from current levels; the firm cites pipeline potential and upcoming program catalysts as the rationale. Benzinga
• Positive Sentiment: A TipRanks summary of HC Wainwright’s coverage emphasizes Coya’s advancing Treg?focused pipeline and near?term catalysts (ALS and FTD) as supporting the Buy rating and long?term upside thesis. Coya Therapeutics: Advancing Treg-Focused Pipeline…
• Neutral Sentiment: Reported short?interest data for March show effectively zero shares on file and a 0.0 days?to?cover figure — an odd/ambiguous data point that neither clearly pressures nor supports the stock given the lack of meaningful short activity.
• Negative Sentiment: HC Wainwright’s updated 2027 forecasts show deeper quarterly and full?year losses than the market consensus (FY2027 EPS forecast of -$1.66 vs. consensus -$1.15), which could concern investors focused on near?term dilution and cash needs despite the Buy rating.
• Negative Sentiment: Recent company results (reported March 16) showed an EPS miss for the quarter (reported -$0.34 vs. -$0.08 expected) despite revenue beating estimates; continued quarterly losses and negative margins remain a risk to sentiment until clear clinical or commercial readouts reduce execution uncertainty.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.